Surrozen

SRZN62

High Growth

$9.09arrow_drop_down2.19%-$0.20

High Growth

SRZN62

$9.09

arrow_drop_down2.19%-$0.20

High Growth

Performance History

Key Stats
Open	$9.29
Prev. Close	$9.30
EPS	-16.94
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$29.73M
PE Ratio	-

	LOW	HIGH
Day Range	8.69	9.32
52 Week Range	4.50	16.19

Ratios







EPS	-16.94

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Surrozen (SRZN)

Surrozen, Inc. (SRZN) is a biotechnology company that specializes in developing regenerative medicines. With a focus on the field of tissue repair and regeneration, Surrozen aims to revolutionize the healthcare industry by providing innovative therapies to patients in need. The company's stock price history reflects its growth and potential in the market. Over the past few years, SRZN's stock price has shown a gradual increase, indicating investor confidence and positive market sentiment.

Surrozen's dedication to developing cutting-edge regenerative medicine has garnered attention from investors and industry experts alike. The company's mission is to leverage the power of stem cells and tissue regeneration to address unmet medical needs. Surrozen's quote on the stock market showcases the company's commitment to driving advancements in the field.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Craig C. Parker M.B.A.
Headquarters: South San Francisco
Employees: 74
Exchange: NASDAQ

Keep an eye on Surrozen

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Surrozen's (SRZN) price per share?

The current price per share for Surrozen (SRZN) is $9.1. The stock has seen a price change of -$0.2 recently, indicating a -2.19% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Surrozen (SRZN)?

For Surrozen (SRZN), the 52-week high is $16.19, which is 77.99% from the current price. The 52-week low is $4.5, the current price is 102.13% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Surrozen (SRZN) a growth stock?

Surrozen (SRZN) has shown an average price growth of -3.66% over the past three years. It has received a score of 98 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Surrozen as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Surrozen (SRZN) stock price performance year to date (YTD)?

As of the latest data, Surrozen (SRZN) has a year-to-date price change of -10.38%. Over the past month, the stock has experienced a price change of -12.54%. Over the last three months, the change has been 6.14%. Over the past six months, the figure is -11.6%.

help

Is Surrozen (SRZN) a profitable company?

Surrozen (SRZN) has a net income of -$43.04M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 12.32% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $12.5M, although specific revenue growth data is currently not available. Operating income is noted at -$45.78M. Furthermore, the EBITDA is -$25.02M.

help

What is the market capitalization of Surrozen (SRZN)?

Surrozen (SRZN) has a market capitalization of $29.74M. The average daily trading volume is 9.18, indicating the stock's liquidity and investor engagement.

News

CLINICAL STUDY

Jun 12, 2024

Surrozen Publishes Study in ‘eLife’ Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling

HEALTH

PRODUCT / SERVICES ANNOUNCEMENT

CLINICAL STUDY

Jun 10, 2024

Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan

CLINICAL STUDY

HEALTH

Jun 4, 2024

Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

HEALTH

PRODUCT / SERVICES ANNOUNCEMENT

May 9, 2024

Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting

CLINICAL STUDY

Apr 3, 2024

Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis

MAJOR SHAREHOLDER ANNOUNCEMENTS

Apr 1, 2024

Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules